Immunome, Inc. (IMNM) - Stock Analysis
Last updated: Apr 26, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong liquidity ⢠Deep operating losses ⢠Negative cash flow IMNM has an exceptionally strong liquidity and low-debt balance sheet, but its deep operating losses, negative cash flow, and poor capital returns make the current investment case highly dependent on future turnaround execution.
Price Behavior
Key Price Behavior Insights: ⢠Uptrend intact ⢠Breakout momentum ⢠Resistance overhead Support Level: $22.90â$22.99 Resistance Level: $24.6â$24.9 IMNM has trended higher over the last month with a strong breakout and support holding near $22.90â$22.99, but it remains capped by $24.6â$24.9 and needs a clean move above that zone to confirm a stronger breakout.
Sentiment & News
Key News Insights: ⢠Technical breakout ⢠Clinical catalyst ⢠Insider sales IMNM shows improving technical momentum and a meaningful clinical catalyst from ASCO presentation selection, though recent insider selling adds a mixed signal.
AI Summary
IMNM has shifted from a cash-burning biotech story to a credible late-stage NDA catalyst driven by positive Phase 3 RINGSIDE data and a strong cash runway, but after the sharp rally the investment case now hinges on flawless regulatory execution and turning one lead asset into durable value before valuation, burn, or insider-sale overhangs cap upside.
Description
Immunome, Inc. is a biopharmaceutical firm that discovers and develops monoclonal antibody therapeutics for oncology and infectious diseases. Its lead oncology candidate, IMM-ONC-01, targets the IL-38 tumor-derived immune checkpoint implicated in tumor immune evasion, and the company also maintains an antibody cocktail program for SARS-CoV-2. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Dec 17 | Dec 24 | IMNM | Immunome, Inc. | Breakthrough Phase 3 clinical results with 84% risk reduction, significant capital raise boosting liquidity, strong technical uptrend with 28% recent price gain, and robust biotech sector backdrop provide a high-potential short-term event-driven opportunity. | Closed | +12.9% |